FDA panel supports approval of Asthmatx device for severe asthma
An FDA panel voted 6-1 to recommend the approval of Asthmatx's Alair Bronchial Thermoplasty System as a first non-drug therapy for patients with severe asthma. The panel cited certain conditions for approval, such as the creation of a patient registry aimed at assessing the long-term safety and efficacy of the device.
Wall Street Journal, The | 10/28
This story published in AdvaMed SmartBrief on 10/29/2009
More from SmartBrief:
FDA says Medtronic heart valve satisfies study goals
Tuesday, July 21, 2009
FDA flags Q-Med on efficacy of knee pain gel
Tuesday, August 18, 2009
Zimmer fails to get FDA panel's support for Dynesys implant
Thursday, November 5, 2009
Get stories like these delivered daily for FREE:
|
AdvaMed SmartBrief
Designed specifically for manufacturers of medical devices, health care information systems and diagnostic products, AdvaMed SmartBrief is a FREE e-mail newsletter. By providing a summary of the day's most important medical technologies news, AdvaMed SmartBrief saves you time and keeps you smart. Learn more |
|